Contraception
Volume 76, Issue 2 , Pages 139-156 , August 2007

Cervical dilation before first-trimester surgical abortion (<14 weeks' gestation)

,Accepted 18 April 2007.

References 

  1. Finer LB, Henshaw SK. Abortion incidence and services in the United States in 2000. Perspect Sex Reprod Health. 2003;35:6–15[Evidence Grade: II-3]
  2. Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004;103:729–737[Evidence Grade: II-2]
  3. Royal College of General Practitioners , Royal College of Obstetricians and Gynaecologists . Induced abortion operations and their early sequelae. J R Coll Gen Pract. 1985;35:175–180[Evidence Grade: II-3]
  4. Andolsek L, Cheng M, Hren M, Ogrinc-Oven M, Ng A, Ratnam S, et al. The safety of local anesthesia and outpatient treatment: a controlled study of induced abortion by vacuum aspiration. Stud Fam Plann. 1977;8:118–124[Evidence Grade: II-2]
  5. Nesheim BI. Induced abortion by the suction method. An analysis of complication rates. Acta Obstet Gynecol Scand. 1984;63:591–595[Evidence Grade: II-2]
  6. Cates W, Schulz KF, Grimes DA. The risks associated with teenage abortion. N Engl J Med. 1983;309:621–624[Evidence Grade: II-2]
  7. Heisterberg L, Kringelbach M. Early complications after induced first-trimester abortion. Acta Obstet Gynecol Scand. 1987;66:201–204[Evidence Grade: II-2]
  8. Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol. 1990;76:129–135[Evidence Grade: II-2]
  9. Ferris LE, McMain-Klein M, Colodny N, Fellows GF, Lamont J. Factors associated with immediate abortion complications. Can Med Assoc J. 1996;154:1677–1685[Evidence Grade: II-2]
  10. Zhou W, Nielsen GL, Moller M, Olsen J. Short-term complications after surgically induced abortions: a register-based study of 56 117 abortions. Acta Obstet Gynecol Scand. 2002;81:331–336[Evidence Grade: II-2]
  11. Grimes DA, Schulz KF, Cates WJ. Prevention of uterine perforation during curettage abortion. JAMA. 1984;251:2108–2111[Evidence Grade: II-2]
  12. Bozorgi N. Statistical analysis of first-trimester pregnancy terminations in an ambulatory surgical center. Am J Obstet Gynecol. 1977;127:763–768[Evidence Grade: II-2]
  13. Hodgson JE, Portmann KC. Complications of 10,453 consecutive first-trimester abortions: a prospective study. Am J Obstet Gynecol. 1974;120:802–807[Evidence Grade: II-2]
  14. Lindell G, Flam F. Management of uterine perforations in connection with legal abortions. Acta Obstet Gynecol Scand. 1995;74:373–375[Evidence Grade: II-2]
  15. King TM, Atienza MF, Burkman RT. The incidence of abdominal surgical procedures in a population undergoing abortion. Am J Obstet Gynecol. 1980;137:530–533[Evidence Grade: II-2]
  16. Schulz KF, Grimes DA, Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet. 1983;1:1182–1185[Evidence Grade: II-2]
  17. Jacot FR, Poulin C, Bilodeau AP, Morin M, Moreau S, Gendron F, et al. A five-year experience with second-trimester induced abortions: no increase in complication rate as compared to the first trimester. Am J Obstet Gynecol. 1993;168:633–637[Evidence Grade: II-2]
  18. Hulka JF, Lefler HT, Anglone A, Lachenbruch PA. A new electronic force monitor to measure factors influencing cervical dilation for vacuum curettage. Am J Obstet Gynecol. 1974;120:166–173[Evidence Grade: II-3]
  19. Novak F, Andolsek L. Comparison of the medical effects of induced abortion by two methods, curettage and vacuum aspiration. In:  Andolsek L editors. The Ljubljana Abortion Study, 1971–1973. Bethesda: National Institutes of Health, Center for Population Research; 1974;[Evidence Grade: II-2]
  20. Hale RW, Pion RJ. Laminaria: an underutilized clinical adjunct. Clin Obstet Gynecol. 1972;15:829–850[Evidence Grade: II-2]
  21. Golditch IM, Glasser MH. The use of laminaria tents for cervical dilatation prior to vacuum aspiration abortion. Am J Obstet Gynecol. 1974;119:481–485[Evidence Grade: II-3]
  22. Niswander KR. Laminaria tents as an aid in suction abortion. Calif Med. 1973;119:11–14[Evidence Grade: II-3]
  23. Hern WM. Laminaria in abortion. Use in 1368 patients in first trimester. Rocky Mt Med J. 1975;72:390–395[Evidence Grade: II-3]
  24. Moberg P. Uterine perforation in connection with vacuum aspiration. Int J Gynaecol Obstet. 1976;14:77–80[Evidence Grade: II-3]
  25. Borell U, Bygdeman M, Leader A, Lundstrom V, Martin JN. Successful first trimester abortion with 15(S) 15-methyl-prostaglandin F2alpha-methyl ester vaginal suppositories. Contraception. 1976;13:87–94[Evidence Grade: II-2]
  26. Gupta JK, Johnson N. Should we use prostaglandins, tents or progesterone antagonists for cervical ripening before first trimester abortion?. Contraception. 1992;46:489–497[Evidence Grade: II-1]
  27. Nicolaides KH, Welch CC, MacPherson MB, Johnson IR, Filshie GM. Lamicel: a new technique for cervical dilatation before first trimester abortion. Br J Obstet Gynaecol. 1983;90:475–479[Evidence Grade: I]
  28. Morris ND, McCallum GI, Hammond L. Preoperative cervical dilatation: a trial of laminaria tents and prostaglandin F2 alpha gel. Aust N Z J Obstet Gynaecol. 1986;26:36–39
  29. Sema S, Hingorani V, Kumar S, Kinra G. Three methods for gradual cervical dilatation prior to vacuum aspiration in late first trimester pregnancy. Contraception. 1983;28:223–231[Evidence Grade: II-3]
  30. Wheeler RG, Schneider K. Properties and safety of cervical dilators. Am J Obstet Gynecol. 1983;146:597–601[Evidence Grade: II-3]
  31. Atrash HK, Hogue CJ. The effect of pregnancy termination on future reproduction. Baillieres Clin Obstet Gynaecol. 1990;4:391–405
  32. Berkowitz GS. An epidemiologic study of preterm delivery. Am J Epidemiol. 1981;113:81–92[Evidence Grade: II-2]
  33. Che Y, Zhou W, Gao E, Olsen J. Induced abortion and prematurity in a subsequent pregnancy: a study from Shanghai. J Obstet Gynaecol. 2001;21:270–273[Evidence Grade: II-2]
  34. Dalaker K, Lichtenberg SM, Okland G. Delayed reproductive complications after induced abortion. Acta Obstet Gynecol Scand. 1979;58:491–494Evidence Grade: II-2]
  35. de Haas I, Harlow BL, Cramer DW, Frigoletto FD. Spontaneous preterm birth: a case–control study. Am J Obstet Gynecol. 1991;165:1290–1296[Evidence Grade: II-2]
  36. Frank PI, McNamee R, Hannaford PC, Kay CR, Hirsch S. The effect of induced abortion on subsequent pregnancy outcome. Br J Obstet Gynaecol. 1991;98:1015–1024[Evidence Grade: II-2]
  37. Henriet L, Kaminski M. Impact of induced abortions on subsequent pregnancy outcome: the 1995 French national perinatal survey. BJOG. 2001;108:1036–1042[Evidence Grade: II-3]
  38. Lopes A, King PA, Duthie SJ, To WK, Ma HK. The impact of multiple induced abortions on the outcome of subsequent pregnancy. Aust N Z J Obstet Gynaecol. 1991;31:41–43[Evidence Grade: II-2]
  39. Mandelson MT, Maden CB, Daling JR. Low birth weight in relation to multiple induced abortions. Am J Public Health. 1992;82:391–394[Evidence Grade: II-2]
  40. Martius JA, Steck T, Oehler MK, Wulf KH. Risk factors associated with preterm (<37+0 weeks) and early preterm birth (<32+0 weeks): univariate and multivariate analysis of 106345 singleton births from the 1994 statewide perinatal survey of Bavaria. Eur J Obstet Gynecol Reprod Biol. 1998;80:183–189[Evidence Grade: II-3]
  41. Meirik O, Nygren KG, Bergstrom R, Gunsjo A. Outcome of delivery subsequent to induced vacuum-aspiration abortion in parous women. Am J Epidemiol. 1982;116:415–429[Evidence Grade: II-2]
  42. Sun Y, Che Y, Gao E, Olsen J, Zhou W. Induced abortion and risk of subsequent miscarriage. Int J Epidemiol. 2003;32:449–454[Evidence Grade: II-2]
  43. Thorp JM, Hartmann KE, Shadigian E. Long-term physical and psychological health consequences of induced abortion: review of the evidence. Obstet Gynecol Surv. 2003;58:67–79[Evidence Grade: III]
  44. Zhou W, Olsen J. Are complications after an induced abortion associated with reproductive failures in a subsequent pregnancy?. Acta Obstet Gynecol Scand. 2003;82:177–181[Evidence Grade: II-2]
  45. Zhou W, Olsen J, Nielsen GL, Sabroe S. Risk of spontaneous abortion following induced abortion is only increased with short interpregnancy interval. J Obstet Gynaecol. 2000;20:49–54[Evidence Grade: II-2]
  46. Zhou W, Sorensen HT, Olsen J. Induced abortion and low birthweight in the following pregnancy. Int J Epidemiol. 2000;29:100–106[Evidence Grade: II-2]
  47. Kaunitz AM, Rovira EZ, Grimes DA, Schulz KF. Abortions that fail. Obstet Gynecol. 1985;66:533–537[Evidence Grade: II-2]
  48. Nathanson BN. Ambulatory abortion: experience with 26,000 cases (July 1, 1970, to August 1, 1971). N Engl J Med. 1972;286:403–407[Evidence Grade: II-2]
  49. Child TJ, Thomas J, Rees M, MacKenzie IZ. Morbidity of first trimester aspiration termination and the seniority of the surgeon. Hum Reprod. 2001;16:875–878[Evidence Grade: II-2]
  50. Wulff GJ, Freiman SM. Elective abortion. Complications seen in a free-standing clinic. Obstet Gynecol. 1977;49:351–357[Evidence Grade: II-3
  51. Goldberg AB, Dean G, Kang MS, Youssof S, Darney PD. Manual versus electric vacuum aspiration for early first-trimester abortion: a controlled study of complication rates. Obstet Gynecol. 2004;103:101–107[Evidence Grade: II-2]
  52. Buehler JW, Schulz KF, Grimes DA, Hogue CJ. The risk of serious complications from induced abortion: do personal characteristics make a difference?. Am J Obstet Gynecol. 1985;153:14–20[Evidence Grade: II-2]
  53. Pridmore BR, Chambers DG. Uterine perforation during surgical abortion: a review of diagnosis, management, and prevention. Aust N Z J Obstet Gynaecol. 1999;39:349–353
  54. Edwards J, Darney PD, Paul M. Surgical abortion in the first trimester. In:  Paul M,  Lichtenberg ES,  Borgatta L, et al. editor. A clinician's guide to medical and surgical abortion. London: Churchill Livingstone; 1999;[Evidence Grade: III]
  55. Lichtenberg ES, Paul M, Jones H. First trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception. 2001;64:345–352[Evidence Grade: II-3]
  56. Olund A, Jonasson A, Kindahl H, Fianu S, Larsson B. The effect of cervical dilatation by laminaria on the plasma levels of 15-keto-13,14-dihydro-PGF2 alpha. Contraception. 1984;30:23–27[Evidence Grade: II-3]
  57. Jonasson A, Larsson B. Contractile activity in the human uterine cervix and corpus during cervical dilatation by laminaria tent in first trimester legal abortions. Acta Obstet Gynecol Scand. 1989;68:401–404[Evidence Grade: II-2]
  58. Sutkin G, Capelle SD, Schlievert PM, Creinin MD. Toxic shock syndrome after laminaria insertion. Obstet Gynecol. 2001;98:959–961
  59. Acharya PS, Gluckman SJ. Bacteremia following placement of intracervical laminaria tents. Clin Infect Dis. 1999;29:695–697
  60. Evaldson GR, Fianu S, Jonasson A, Larsson B, Nord CE, Olund AR. Does the hygroscopic property of the laminaria tent imply a risk for ascending infection in legal abortions? A microbiological study. Acta Obstet Gynecol Scand. 1986;65:257–261[Evidence Grade: II-1]
  61. Jonasson A, Larsson B, Bygdeman S, Forsum U. The influence of cervical dilatation by laminaria tent and with Hegar dilators on the intrauterine microflora and the rate of postabortal pelvic inflammatory disease. Acta Obstet Gynecol Scand. 1989;68:405–410
  62. Kim SH, Chang YH, Kim WK, Kim YK, Cho SH, Kim YY, et al. Two cases of anaphylaxis after laminaria insertion. J Korean Med Sci. 2003;18:886–888
  63. Chanda M, Mackenzie P, Day JH. Hypersensitivity reactions following laminaria placement. Contraception. 2000;62:105–106
  64. Nguyen MT, Hoffman DR. Anaphylaxis to laminaria. J Allergy Clin Immunol. 1995;95:138–139[Evidence Grade: III]
  65. Usta IM, Khalil A. Long-term complications and ultrasound findings in retained Dilapan fragments. Int J Gynaecol Obstet. 1999;65:311–312
  66. Canvin J. Personal communication: F.E.M.A. International, U.S. Headquarters: J.C.E.C. Company Inc., 2006. Evidence Grade: III.
  67. Nicolaides KH, Welch CC, Koullapis EN, Filshie GM. Cervical dilatation by Lamicel—studies on the mechanism of action. Br J Obstet Gynaecol. 1983;90:1060–1064[Evidence Grade: II-3]
  68. Grimes DA, Ray IG, Middleton CJ. Lamicel versus laminaria for cervical dilation before early second-trimester abortion: a randomized clinical trial. Obstet Gynecol. 1987;69:887–890
  69. World Health Organization's Task Force on Prostaglandins for Fertility Regulation . Vaginal administration of 15-methyl-PGF2 alpha methyl ester for preoperative cervical dilatation. Contraception. 1981;23:251–259[Evidence Grade: I]
  70. Meckstroth KR, Darney PD. Prostaglandins for first-trimester termination. Best Pract Res Clin Obstet Gynaecol. 2003;17:745–763
  71. O'Brien WF. The role of prostaglandins in labor and delivery. Clin Perinatol. 1995;22:973–984
  72. Thomson Healthcare Inc . 2006 red book. Montvale, NJ: Thomson PDR; 2006;[Evidence Grade: III]
  73. Eckerhovd E, Radulovic N, Norstrom A. Gemeprost versus misoprostol for cervical priming before first-trimester abortion: a randomized controlled trial. Obstet Gynecol. 2003;101:722–725
  74. Henry AM, Haukkamaa M. Comparison of vaginal misoprostol and gemeprost as pre-treatment in first trimester pregnancy interruption. Br J Obstet Gynaecol. 1999;106:540–543
  75. Platz-Christensen JJ, Nielsen S, Hamberger L. Is misoprostol the drug of choice for induced cervical ripening in early pregnancy termination?. Acta Obstet Gynecol Scand. 1995;74:809–812[Evidence Grade: I]
  76. el-Refaey H, Calder L, Wheatley DN, Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. Lancet. 1994;343:1207–1209
  77. Sparrow MJ, Tait JD, Stone PR. Vaginal dinoprostone versus oral misoprostol for predilatation of the cervix in first trimester surgical abortion. Aust N Z J Obstet Gynaecol. 1998;38:64–68
  78. Bokstrom H, Atterfelt P, Alexandersson M, Brannstrom M, Norstrom A. Preoperative cervical softening before first trimester legal abortion by mifepristone and misoprostol: a double-blind, randomized, clinical, biochemical, and immunohistochemical study. Contraception. 1998;58:157–163
  79. Johnson N, Bryce FC. Could antiprogesterones be used as alternative cervical ripening agents?. Am J Obstet Gynecol. 1990;162:688–690[Evidence Grade: II-3]
  80. Durlot F, Dubois C, Brunerie J, Frydman R. Efficacy of progesterone antagonist RU486 (mifepristone) for pre-operative cervical dilatation during first trimester abortion. Hum Reprod. 1988;3:583–584
  81. Radestad A, Christensen NJ, Stromberg L. Induced cervical ripening with mifepristone in first trimester abortion. A double-blind randomized biomechanical study. Contraception. 1988;38:301–312
  82. Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol. 1988;95:126–134[Evidence Grade: II-2]
  83. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92
  84. Danielsson KG, Marions L, Rodriguez A, Spur BW, Wong PY, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol. 1999;93:275–280
  85. Khan RU, El-Refaey H, Sharma S, Sooranna D, Stafford M. Oral, rectal, and vaginal pharmacokinetics of misoprostol. Obstet Gynecol. 2004;103:866–870
  86. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332–336
  87. Singh K, Fong YF, Prasad RN, Dong F. Does an acidic medium enhance the efficacy of vaginal misoprostol for pre-abortion cervical priming?. Hum Reprod. 1999;14:1635–1637[Evidence Grade: I]
  88. Creinin MD, Carbonell JL, Schwartz JL, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999;59:11–16
  89. Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum Reprod. 2000;15:1159–1162
  90. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod. 2004;19:81–84[Evidence Grade: II-1]
  91. Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception. 2005;71:22–25[Evidence Grade: I]
  92. Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: drug absorption and uterine response. Obstet Gynecol. 2006;108:582–590
  93. Li CFI, Wong CYG, Chan CPB, Ho PC. A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. Contraception. 2003;67:101–105
  94. World Health Organization . Safe abortion: technical and policy guidance for health systems. Geneva: WHO; 2003;[Evidence Grade: III]
  95. Royal College of Obstetricians & Gynaecologists . The care of women requesting induced abortion. London: RCOG Press; 2004;[Evidence Grade: III]
  96. National Abortion Federation . 2006 clinical policy guidelines. Washington (DC): National Abortion Federation; 2006;[Evidence Grade: III]
  97. Planned Parenthood Federation of America Inc . PPFA manual of medical standards and guidelines. New York: PPFA; 2006;[Evidence Grade: III]
  98. Baldock S. Personal communication: Marie Stopes procedure: Marie Stopes International, 2006. Evidence Grade: III.
  99. Lawrie A, Penney G, Templeton A. A randomised comparison of oral and vaginal misoprostol for cervical priming before suction termination of pregnancy. Br J Obstet Gynaecol. 1996;103:1117–1119
  100. Aronsson A, Helstrom L, Gemzell-Danielsson K. Sublingual compared with oral misoprostol for cervical dilatation prior to vacuum aspiration: a randomized comparison. Contraception. 2004;69:165–169
  101. Ashok PW, Hamoda H, Nathani F, Flett GM, Templeton A. Randomised controlled study comparing oral and vaginal misoprostol for cervical priming prior to surgical termination of pregnancy. BJOG. 2003;110:1057–1061
  102. Bugalho A, Bique C, Almeida L, Bergstrom S. Application of vaginal misoprostol before cervical dilatation to facilitate first-trimester pregnancy interruption. Obstet Gynecol. 1994;83:729–731
  103. Cakir L, Dilbaz B, Caliskan E, Dede FS, Dilbaz S, Haberal A. Comparison of oral and vaginal misoprostol for cervical ripening before manual vacuum aspiration of first trimester pregnancy under local anesthesia: a randomized placebo-controlled study. Contraception. 2005;71:337–342
  104. Carbonell JL, Mari J, Valero F, Llorente M, Salvador I, Varela L, et al. Sublingual versus vaginal misoprostol (400 μg) for cervical priming in first-trimester abortion: a randomized trial. Contraception. 2006;74:328–333
  105. Carbonell JL, Velazco A, Rodriguez Y, Tanda R, Sanchez C, Barambio S, et al. Oral versus vaginal misoprostol for cervical priming in first-trimester abortion: a randomized trial. Eur J Contracept Reprod Health Care. 2001;6:134–140
  106. de Jonge ET, Jewkes R, Levin J, Rees H. Randomised controlled trial of the efficacy of misoprostol used as a cervical ripening agent prior to termination of pregnancy in the first trimester. S Afr Med J. 2000;90:256–262[Evidence Grade: I]
  107. Ficicioglu C, Tasdemir M, Tasdemir S. Effect of vaginal misoprostol application for cervical softening in pregnancy interruption before ten weeks of gestation. Acta Obstet Gynecol Scand. 1996;75:54–56
  108. Fong YF, Singh K, Prasad RN. A comparative study using two dose regimens (200 microg or 400 microg) of vaginal misoprostol for pre-operative cervical dilatation in first trimester nulliparae. Br J Obstet Gynaecol. 1998;105:413–417
  109. Golland IM, Vaughan-Williams CA, Elstein M. A comparison of osmotic dilators, Lamicel and Dilapan, and a prostaglandin E1analogue, gemeprost, for ripening the cervix before legal abortion. J Obstet Gynaecol. 1989;9:210–212
  110. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized controlled comparison of sublingual and vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. Am J Obstet Gynecol. 2004;190:55–59[Evidence Grade: I]
  111. Kline SB, Meng H, Munsick RA. Cervical dilation from laminaria tents and synthetic osmotic dilators used for 6 hours before abortion. Obstet Gynecol. 1995;86:931–935
  112. Limongelli MD, Belletti F, Cecere AT, Oliva L, Carlomagno G. Vaginal misoprostol as a cervical ripening agent prior to suction curettage for first-trimester termination of pregnancy. Italian Journal of Gynaecology and Obstetrics. 2004;16:32–34[Evidence Grade: II-1]
  113. MacIsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol. 1999;93:766–770[Evidence Grade: I]
  114. Ngai SW, Chan YM, Tang OS, Ho PC. The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial. Hum Reprod. 1999;14:2139–2142
  115. Ngai SW, Tang OS, Lao T, Ho PC, Ma HK. Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy. Hum Reprod. 1995;10:1220–1222
  116. Okanlomo KA, Ngotho D, Moodley J. Effect of misoprostol for cervical ripening prior to pregnancy interruption before twelve weeks of gestation. East Afr Med J. 1999;76:552–555
  117. Oppegaard KS, Abdelnoor M, Nesheim BI, Jerve F, Eskild A. The use of oral misoprostol for pre-abortion cervical priming: a randomised controlled trial of 400 versus 200 microg in first trimester pregnancies. BJOG. 2004;111:154–159
  118. Saxena P, Salhan S, Sarda N. Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy. Contraception. 2003;67:213–217
  119. Saxena P, Salhan S, Sarda N. Comparison between the sublingual and oral route of misoprostol for pre-abortion cervical priming in first trimester abortions. Hum Reprod. 2004;19:77–80[Evidence Grade: II-1]
  120. Saxena P, Salhan S, Sarda N. Sublingual versus vaginal route of misoprostol for cervical ripening prior to surgical termination of first trimester abortions. Eur J Obstet Gynecol Reprod Biol. 2006;125:109–113[Evidence Grade: II-1]
  121. Sharma S, Refaey H, Stafford M, Purkayastha S, Parry M, Axby H. Oral versus vaginal misoprostol administered one hour before surgical termination of pregnancy: a randomised controlled trial. BJOG. 2005;112:456–460
  122. Singh K, Fong YF, Prasad RN, Dong F. Randomized trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming. Obstet Gynecol. 1998;92:795–798
  123. Tang OS, Mok KH, Ho PC. A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester. Hum Reprod. 2004;19:1101–1104[Evidence Grade: I]
  124. Vimala N, Mittal S, Kumar S. Sublingual misoprostol for preabortion cervical ripening in first-trimester pregnancy termination. Contraception. 2003;67:295–297
  125. Vimala N, Mittal S, Kumar S, Dadhwal V, Sharma Y. A randomized comparison of sublingual and vaginal misoprostol for cervical priming before suction termination of first-trimester pregnancy. Contraception. 2004;70:117–120
  126. Goldberg AB, Drey EA, Whitaker AK, Kang MS, Meckstroth KR, Darney PD. Misoprostol compared with laminaria before early second-trimester surgical abortion: a randomized trial. Obstet Gynecol. 2005;106:234–241
  127. Kiran U, Amin P, Penketh RJ. Self-administration of vaginal misoprostol after mifepristone for termination of pregnancy: patient acceptability. J Obstet Gynaecol. 2006;26:679–681[Evidence Grade: II-3]
  128. Kiran U, Amin P, Penketh RJ. Self-administration of misoprostol for termination of pregnancy: safety and efficacy. J Obstet Gynaecol. 2004;24:155–156[Evidence Grade: II-3]
  129. Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 2000;284:1948–1953[Evidence Grade: I]
  130. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002;66:247–250
  131. Oppegaard KS, Qvigstad E, Nesheim BI. Oral versus self-administered vaginal misoprostol at home before surgical termination of pregnancy: a randomised controlled trial. BJOG. 2006;113:58–64
  132. Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F, et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med. 1998;338:1881–1885[Evidence Grade: II-2]
  133. Schuler L, Pastuszak A, Sanseverino TV, Orioli IM, Brunoni D, Ashton-Prolla P, et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol. 1999;13:147–151[Evidence Grade: II-2]
  134. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayama SM, et al. Prenatal exposure to misoprostol and vascular disruption defects: a case–control study. Am J Med Genet. 2000;95:302–306[Evidence Grade: II-2]
  135. Eaton CJ, Cohn F, Bollinger CC. Laminaria tent as a cervical dilator prior to aspiration-type therapeutic abortion. Obstet Gynecol. 1972;39:535–537[Evidence Grade: II-3]
  136. Bryman I, Granberg S, Norstrom A. Reduced incidence of postoperative endometritis by the use of Laminaria tents in connection with first trimester abortion. Acta Obstet Gynecol Scand. 1988;67:323–325
  137. Munsick RA, Fineberg NS. Cervical dilation from multiple laminaria tents used for abortion. Obstet Gynecol. 1996;87:726–729[Evidence Grade: II-2]
  138. Manabe Y, Mori T, Yoshida Y. Decidual morphology and F prostaglandin in amniotic fluid in stretch-induced abortion. Obstet Gynecol. 1984;64:661–665
  139. Krammer J, O'Brien WF. Mechanical methods of cervical ripening. Clin Obstet Gynecol. 1995;38:280–286
  140. Bokstrom H, Wiqvist N. Preoperative dilatation of the cervix at legal abortion with a synthetic, fast-swelling hygroscopic tent. Acta Obstet Gynecol Scand. 1989;68:313–318[Evidence Grade: II-3]
  141. Skjeldestad FE, Tuveng J. Cervical dilatation with Lamicel in first trimester therapeutic abortion. Int J Gynaecol Obstet. 1990;33:153–157
  142. Darney PD, Dorward K. Cervical dilation before first-trimester elective abortion: a controlled comparison of meteneprost, laminaria, and hypan. Obstet Gynecol. 1987;70:397–400
  143. Borgatta L, Barad D. Prolonged retention of laminaria fragments: an unusual complication of laminaria usage. Obstet Gynecol. 1991;78:988–990
  144. Liang ST, Woo JS, Tang GW. Ultrasonic localization of a displaced laminaria tent. Am J Obstet Gynecol. 1983;146:988–989
  145. Hern WM. Laminaria versus Dilapan osmotic cervical dilators for outpatient dilation and evacuation abortion: randomized cohort comparison of 1001 patients. Am J Obstet Gynecol. 1994;171:1324–1328
  146. Wells EC, Hulka JF. Cervical dilation: a comparison of Lamicel and Dilapan. Am J Obstet Gynecol. 1989;161:1124–1126
  147. Wiebe ER, Rawling MJ. Vaginal misoprostol before first trimester abortion. Int J Gynaecol Obstet. 1998;60:175–176
  148. Edwards D, Aitken R, Begg A, MacKay P, Marchant R. Predilatation of the cervix before suction curettage for therapeutic abortion in early pregnancy. Aust NZ J Obstet Gynaecol. 1994;34:103–104[Evidence Grade: II-3]
  149. von Hertzen H. Personal communication: World Health Organization, 2007. Evidence Grade: III.
  150. Singh K, Fong YF, Prasad RN, Dong F. Vaginal misoprostol for pre-abortion cervical priming: is there an optimal evacuation time interval?. Br J Obstet Gynaecol. 1999;106:266–269[Evidence Grade: I]
  151. Singh K, Fong YF, Prasad RN, Dong F. Evacuation interval after vaginal misoprostol for preabortion cervical priming: a randomized trial. Obstet Gynecol. 1999;94:431–434
  152. Burnett MA, Corbett CA, Gertenstein RJ. A randomized trial of laminaria tents versus vaginal misoprostol for cervical ripening in first trimester surgical abortion. J Obstet Gynaecol Can. 2005;27:38–42
  153. Vimala N, Mittal S, Kumar S. Sublingual misoprostol before first trimester abortion: a comparative study using two dose regimens. Indian J Med Sci. 2004;58:54–61
  154. Inal MM, Ertopcu K, Arici A, Ozelmas I. The effect of oral versus vaginal misoprostol on cervical dilatation in first-trimester abortion: a double-blind, randomized study. Eur J Contracept Reprod Health Care. 2003;8:197–202[Evidence Grade: I]
  155. Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet Gynecol. 1997;90:735–738
  156. Patel A, Talmont E, Morfesis J, Pelta M, Gatter M, Momtaz MR, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception. 2006;73:420–430[Evidence Grade: II-3]
  157. Hall G, Ekblom A, Persson E, Irestedt L. Effects of prostaglandin treatment and paracervical blockade on postoperative pain in patients undergoing first trimester abortion in general anesthesia. Acta Obstet Gynecol Scand. 1997;76:868–872

PII: S0010-7824(07)00152-7

doi: 10.1016/j.contraception.2007.05.001

Contraception
Volume 76, Issue 2 , Pages 139-156 , August 2007

Article Tools

* Image Usage & Resolution